# NCATS DPI TDB INFUSE HEALTH EQUITY PRECLINICAL DEVELOPMENT

> **NIH NIH N02** · MITRE CORPORATION · 2024 · $265,336

## Abstract

The Health FFRDC Operator to provide independent, expert
technical, analytical, and subject matter support to conduct a survey of the rare disease
landscape, develop and identify best practices for infusing an equity perspective, and lay the
groundwork for a pilot of preclinical and therapeutics research into rare diseases with health
disparity implications.
The Health FFRDC will provide the timely integration and application of many disciplines and
functional specialties that are too broad and complex to acquire through individual, competitive
procurements with commercial contractors.

## Key facts

- **NIH application ID:** 11042042
- **Project number:** 75N95022F00142-P00005-0-1
- **Recipient organization:** MITRE CORPORATION
- **Principal Investigator:** PAULA HUSTON
- **Activity code:** N02 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $265,336
- **Award type:** —
- **Project period:** 2022-09-12 → 2024-09-14

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11042042

## Citation

> US National Institutes of Health, RePORTER application 11042042, NCATS DPI TDB INFUSE HEALTH EQUITY PRECLINICAL DEVELOPMENT (75N95022F00142-P00005-0-1). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/11042042. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*